California AB1320 prohibits state agencies from awarding noncompetitive contracts for opioid antagonists to contractors involved in opioid epidemic.

California AB1320, known as the California Affordable Drug Manufacturing Act of 2020, adds a new section to the Health and Safety Code. It defines "opioid antagonist" as a drug that neutralizes opioid effects, such as naloxone hydrochloride. The bill mandates that state agencies cannot award noncompetitive contracts for opioid antagonists to contractors who have settled multistate agreements for contributing to the opioid epidemic. Contracts violating this provision are void and unenforceable, and the rule applies retroactively to contracts made before January 1, 2026.

California AB1320 prohibits state agencies from awarding noncompetitive contracts for opioid antagonists to contractors involved in opioid epidemic.

California AB1320, known as the California Affordable Drug Manufacturing Act of 2020, adds a new section to the Health and Safety Code. It defines "opioid antagonist" as a drug that neutralizes opioid effects, such as naloxone hydrochloride. The bill mandates that state agencies cannot award noncompetitive contracts for opioid antagonists to contractors who have settled multistate agreements for contributing to the opioid epidemic. Contracts violating this provision are void and unenforceable, and the rule applies retroactively to contracts made before January 1, 2026.